Wu Jia, Zhang Yonggang, Liao Xiaoyang, Lei Yi
Department of International Medical Center/Ward of General Practice, West China Hospital, Sichuan University, Chengdu, China.
Department of Periodical Press, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Front Med (Lausanne). 2020 Jul 21;7:350. doi: 10.3389/fmed.2020.00350. eCollection 2020.
Anticoagulation therapy is an important method of preventing stroke in individuals with atrial fibrillation (AF). Atrial fibrillation is a quivering or irregular heartbeat that can lead to blood clots, stroke, heart failure, and other heart-related complications. Clinical guidelines on AF consistently recommend long-term oral warfarin to treat valvular atrial fibrillation (VAF). However, due to varying risks of blood clots and stroke associated with different types of non-valvular atrial fibrillation NVAF, it is unclear whether direct oral anticoagulant (DOAC) can replace warfarin. Despite a recent increase in evidence on the effectiveness and the importance of anticoagulant therapy in preventing thromboembolic events associated with NVAF, clinical prevention strategies remain complex. Given the complexities associated with clinical use of anticoagulants for patients with NVAF, this review aims to offer guidance on patient anticoagulant use based on current available evidence.
抗凝治疗是预防心房颤动（AF）患者中风的重要方法。心房颤动是一种颤动或不规则的心跳，可导致血液凝块、中风、心力衰竭和其他与心脏相关的并发症。AF临床指南一直推荐长期口服华法林治疗瓣膜性心房颤动（VAF）。然而，由于不同类型的非瓣膜性心房颤动（NVAF）相关的血栓形成和中风风险各异，尚不清楚直接口服抗凝剂（DOAC）是否能取代华法林。尽管最近有越来越多的证据表明抗凝治疗在预防与NVAF相关的血栓栓塞事件方面的有效性和重要性，但临床预防策略仍然复杂。鉴于NVAF患者使用抗凝剂的临床复杂性，本综述旨在根据现有证据为患者抗凝剂的使用提供指导。
